P845 ATLAS 1: the first Phase 3 study evaluating the new...

P845 ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections

G.R. Corey, M.E. Stryjewski, W.D. O'Riordan, V.G. Fowler Jr, D.P. Ross, A. Hopkins, M.M. Kitt, S.L. Barriere
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Year:
2007
Language:
english
DOI:
10.1016/s0924-8579(07)70686-6
File:
PDF, 86 KB
english, 2007
Conversion to is in progress
Conversion to is failed